Creating interdisciplinary medical education to advance psychotropic deprescribing, safer tapering, and recovery. 501(c)(3) nonprofit. Join & donate today!
United States
Joined August 2024
- Tweets2K
- Following552
- Followers501
- Likes950
Psychotropic Deprescribing Council retweeted
The thing that helped the most is time, or to be generous, time on the first antidepressant. Here's another terrific study, CO-MED, that suggest that mechanism if irrelevant and that that more drugs have more side effects. No one wants to talk about it.
psychiatryonline.org/doi/10.…
Psychotropic Deprescribing Council retweeted
@jack_goulder No history of psychiatry is complete without examination of the role of primary care in psychiatric diagnosis & treatment for the last 35 years. Powers-that-be claimed antidepressants were so safe & effective, no specialist training needed. Made billion$ for pharma.
"No placebo arm" is traditional in psychiatry research. You'd think the researchers wanted to find significant results for their experimental arm.
In 2017, the VA ran a large RCT (VAST-D) in 1,522 veterans with depression.
Three arms:
(1) adding the antipsychotic Abilify (aripiprazole)
(2) adding the NDRI Wellbutrin (bupropion)
(3) switching to Wellbutrin.
Abilify did statistically better, but the raw numbers are not impressive, see graphic. Groups started with QIDS of 16.5–17 and ended 8.9-10.1.
Some took this to mean adding an antipsychotic beats Wellbutrin. There was no placebo arm, so we can't know whether any of these would do better than time and attention.
The authors: "augmentation with aripiprazole resulted in a statistically significant but only modestly increased likelihood of remission."
Also the meds had side effects:
• Abilify akathisia (14.9% vs 4.3%), sedation (14.5% vs 7.2%), weight gain (25.2% vs 5.2%).
• Wellbutrin anxiety (24.3% vs 16.6%), irritability (6.3% vs 1.4%).
Ref: Mohamed et al., 2017. JAMA, 318(2), 132–145.
Psychotropic Deprescribing Council retweeted
We learned nothing from the disastrous #OxyContin tragedy.
Big Pharma/Venture Capital/Biotech startups are pouring billions prematurely hyping ketamine/psilocybin/MDMA.
Long term efficacy unclear & safe only in highly controlled/very expensive settings.
Result will surely be massive increase in very dangerous street use.
Researchers are optimistic about psychedelic drugs as potential treatments for depression and mood disorders, despite pushback having stalled the field
go.nature.com/4e1WDEM
As usual in psychiatric, the findings neglect the environments that might foster these attitudes in teens, such as interpersonal behaviors handed down in families, regional alcoholism, & neighborhood political leanings.
Psychotropic Deprescribing Council retweeted
Week 7 of the Symptom Patterns Series (Series 4)
Mixed and Overlapping Patterns
Some withdrawal symptoms may fit one recognizable pattern. Others may span several — or fit none of them neatly.
Earlier weeks described patterns involving threat and arousal, autonomic symptoms, movement, and changes in thinking, sensing, and self-experience. In practice, these patterns can overlap.
A person’s picture may include fear and a racing heart (threat/arousal) alongside tremor and difficulty keeping still (motor). Or digestive upset and light-headedness (autonomic) alongside mental fogginess (thinking) and sound sensitivity (sensory).
Appearing together does not mean sharing one cause.
Some symptoms are harder to place — flu-like feelings, skin symptoms, or new intolerances. Others, such as what some people call “benzo belly,” may overlap several areas rather than fitting one pattern. Naming them does not explain their cause.
Overlap is not a flaw — it is part of the picture. These patterns are a shared language for patients and clinicians. They are not diagnoses and do not establish why symptoms occur.
New or changing symptoms deserve individual medical evaluation.
thebenzotaperdoctor.com/post…
#BenzoWithdrawal #NervousSystem #Neuroscience
New psychiatric diagnosis for people who become physiologically dependent on a prescribed opioid: complex persistent opioid dependence (CPOD). But not addicted - that's opioid use disorder (OUD).
hmpgloballearningnetwork.com…
You, too, propofol? "Have you ever noticed that some of your critically ill patients become agitated & confused when their propofol infusions are being tapered or discontinued?"
Managing Propofol Withdrawal psychiatrist.com/pcc/manifes…
This makes too much sense.
If we want to be evidence-based, as we should, then any clinical trial must follow the same scientific method: if "symptom relief" in the intervention group is high, but not higher than "placebo" (and we can argue what that placebo is or should be in various patient populations), then we can't call this intervention effective.
Psychotropic Deprescribing Council retweeted
Dr. Ostacher, a recent article in Nature:
"What the field has not built, with equivalent rigor, is a science of what happens when the treatment stops."
Kim, B. (2026). The neuropsychopharmacology of treatment discontinuation. Neuropsychopharmacology. doi.org/10.1038/s41386-026-0…
Psychotropic Deprescribing Council retweeted
It would be great to have RCTs, but they're not a prerequisite for calling it "science." It's also worth remembering WHY we don't have RCTs--not because there's nothing worth investigating, but because of lack of funding. Most of science is done without RCTs, and for now we have to do our best to make inferences with available data. But it's also more than "conjecture and clinical experience."
The underlying biology aligns with with the clinical experience of many patients needing to taper to very low doses (ie hyperbolic dose occupancy curves) although the mechanistic picture is incomplete (here is where I plug @BShapiroMD and I's recent paper that you've seen as a next step). There is observational data as well, and much of what we do in psychiatry is based on observational data.
The fact that we know this issue affects many patients should prompt us to call for more research, but it shouldn't make us dismiss whatever evidence we do have. Good science is about making inferences with limited data, and we can't afford to sit back and wait for "perfect" data--too many patients are suffering for that!
In many studies, the quality of the relationship between a patient and their doctor or therapist has emerged as a prominent factor for good outcomes.
the quality of the relationship between a patient and their therapist was one of the strongest predictors of treatment outcome in a psilocybin study
not everyone needs a therapist in the room, obviously, but for people with TRD or PTSD... they likely do.
frontiersin.org/journals/pha…
Psychotropic Deprescribing Council retweeted
📢 I am very happy to report that my new paper on why psychotherapies should not be used as standard treatment for #POTS is accepted for publication. 🎉
Only the abstract is published so far; full paper to follow.
frontiersin.org/journals/neu…
Psychotropic Deprescribing Council retweeted
"Diagnostic revision may correct error; it may also threaten identity, access to support and self-understanding, fall unequally on particular groups, or become a mechanism for rationing" pubmed.ncbi.nlm.nih.gov/4292… From @DrMariosAdamou et al. De-diagnosis is a rising topic.
Psychotropic Deprescribing Council retweeted
Great piece explaining current profusion of diagnostic fads & obstacles to corrective "de-diagnosis".
3 causes:
1)Demand led self-diagnosis rather than careful clinical evaluation 2)Identity-conferring rather than descriptive labeling 3)Self-reinforcing rather correctable
"Diagnostic revision may correct error; it may also threaten identity, access to support and self-understanding, fall unequally on particular groups, or become a mechanism for rationing" pubmed.ncbi.nlm.nih.gov/4292… From @DrMariosAdamou et al. De-diagnosis is a rising topic.
Psychotropic Deprescribing Council retweeted
Some therapists work to develop their clinical skill.
Some work to build their online brands.
It’s probably good to recognize the difference.
So under-researched, post-partum conditions are relegated to psychiatry, the last resort for unusual behaviors, instead of being addressed by gynecological endocrinology. Why are women treated this way?
This caused not only overdiagnosis of Bipolar-II in general, but it was misinterpreted to mean that activation, a common adverse reaction to antidepressants, was diagnostic for bipolar disorder.
It is not.
Psychotropic Deprescribing Council retweeted
Road to hell is paved with good intentions & bad unintended consequences.
We included Bipolar-II in DSM-IV to reduce risk of antidepressants causing mania/rapid cycling in people with bipolar risk.
But Pharma promoted massive over-diagnosis & overuse of harmful antipsychotics.
This Post is from an account that no longer exists. Learn more
Article specifies PSYCHOTHERAPY, not the reflexive throwing of antidepressants at women that usually results from screening, which is known to produce many false positives.
Of course "depressed" mothers affect offspring -- often this is in a familial context of financial strain.
Many research studies have shown that untreated depression during pregnancy adversely impacts the mental health of the child as well as the mother. ow.ly/R4wK50ZZ4oE
